Prosecution Insights
Last updated: September 17, 2026
Application No. 19/009,814

URINARY CATHETER

Non-Final OA §DP
Filed
Jan 03, 2025
Priority
Jan 20, 2017 — GB 1701027.3 +3 more
Examiner
MARCETICH, ADAM M
Art Unit
Tech Center
Assignee
The Flume Catheter Company Limited
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
1y 3m
Est. Remaining
92%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
990 granted / 1363 resolved
+12.6% vs TC avg
Strong +19% interview lift
Without
With
+18.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
48 currently pending
Career history
1389
Total Applications
across all art units

Statute-Specific Performance

§101
3.1%
-36.9% vs TC avg
§103
48.0%
+8.0% vs TC avg
§102
15.4%
-24.6% vs TC avg
§112
21.0%
-19.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1363 resolved cases

Office Action

§DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Acknowledgment is made of applicant's claim for foreign priority under 35 U.S.C. 119(a)-(d). A certified copy of Parent Application 1701027.3, filed in The United Kingdom on 20 January 2017 has been received in parent Application 16479701 on 22 July 2019. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b). Claims 1-20 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-20 of Havard ‘468; John et al. (US 11446468 B2). Regarding pending claim 1, Havard ‘468 claims all limitations in patented claim 1. Havard ‘468 claims additional features including a drainage opening and the balloon comprising first and second regions secured to the shaft (claim 1). However, Havard ‘468 claims all features of pending claim 1. Regarding pending claims 2-20, Havard ‘468 claims all limitations in patented claims 1-20 as shown in Table 1. Table 1: Havard ‘468 double patenting Pending claim Havard ‘468 Pending claim Havard ‘468 Pending claim Havard ‘468 2 1 9 1, 9 16 1, 16 3 1, 2, 3 10 1, 10 17 1, 17 4 1, 4 11 1, 11 18 1, 18 5 1, 5 12 1, 12 19 1, 19 6 1, 6 13 1, 13 20 1, 20 7 1, 7 14 1, 14 8 1, 8 15 1, 15 Claims 1-20 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-20 of Havard ‘142; John et al. (US 12214142 B2). Regarding pending claim 1, Havard ‘142 claims all limitations in patented claim 1. Havard ‘142 claims additional features including a drainage opening that communicates with a drainage lumen in the shaft (claim 1). However, Havard ‘142 claims all features of pending claim 1. Regarding pending claims 2-20, Havard ‘142 claims all limitations in patented claims 1-20 as shown in Table 2. Table 2: Havard ‘142 double patenting Pending claim Havard ‘142 Pending claim Havard ‘142 Pending claim Havard ‘142 2 1, 2 9 1, 10, 11 16 1, 17 3 1, 2, 3 10 1, 12 17 1, 18 4 1, 9 11 1, 13 18 1, 2, 8 5 1, 2, 4 12 1, 14 19 1, 19 6 1, 2, 5 13 1, 15 20 1, 20 7 1, 2, 6 14 1, 16 8 1, 10 15 1, 2, 7 Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Harada, Kinya EP 0351734 B1 Hannon; David et al. WO 2010090671 A2 Kieturakis; Maciej J. et al. US 20060173483 A1 Gim; Chang Uk US 20120215053 A1 Gobel; Fred US 20140296831 A1 Any inquiry concerning this communication or earlier communications from the examiner should be directed to: Tel 571-272-2590 Fax 571-273-2590 Email Adam.Marcetich@uspto.gov The Examiner can be reached 8am-4pm Mon-Fri. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Rebecca Eisenberg can be reached at 571-270-5879. The fax phone number for the organization where this application is assigned is 571-273-8300. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Adam Marcetich/ Primary Examiner, Art Unit 3781
Read full office action

Prosecution Timeline

Jan 03, 2025
Application Filed
Aug 24, 2026
Non-Final Rejection mailed — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12734285
ADAPTABLE WOUND DRAINAGE SYSTEM
2y 9m to grant Granted Sep 15, 2026
Patent 12728244
COMBINED PYELO-URETERAL STENT
3y 7m to grant Granted Sep 08, 2026
Patent 12721940
CHEST DRAINAGE SYSTEMS AND METHODS
2y 8m to grant Granted Sep 01, 2026
Patent 12721942
SURGICAL DRAINS AND SYSTEMS AND METHODS FOR USING SAME
2y 2m to grant Granted Sep 01, 2026
Patent 12702587
OPHTHALMIC DEVICE
3y 9m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
92%
With Interview (+18.9%)
2y 11m (~1y 3m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1363 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month